Medpace Holdings Inc vs Workday Inc — how do they compare? Medpace Holdings Inc trades at $530.31 (market cap $15.08B), while Workday Inc trades at $144.05 (market cap $36.36B). The key difference: Workday Inc is far larger — about 2.4× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Workday Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | WDAY | |
|---|---|---|
Market Cap | $15.08B | $36.36B |
Sector | Technology | Technology |
52-Week High | $620.59 | $247.69 |
52-Week Low | $308.88 | $112.55 |
Enterprise Value | $14.55B | $35.81B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Workday (WDAY) trades at $146.92, up 1.48% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $151.36. The company has beaten EPS estimates for three consecutive quarters, with Q2 2026 expected at $2.62. Revenue grew to $8.45 billion in 2025, though net income margin compressed to 6.22% from 19.02% in 2024. Positive sentiment is driven by AI product expansion, but a lawsuit over AI bias and net cash outflows present headwinds.
WDAY offers growth potential with strong subscription revenue and AI-driven deal expansion, yet high P/E of 45.1 suggests premium valuation. Risks include competitive pressures, regulatory scrutiny, and reliance on enterprise spending. Analyst consensus is bullish with 55.55% buy ratings, but investors should monitor execution on profitability and legal challenges.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →